Overview

Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women

Status:
Withdrawn
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The specific purpose of this study is to provide objective data in prospective open label design (n=40) to support the use of Mirabegron as a treatment for pain related urinary frequency and urgency. Women with bladder pain have a poor response to traditional anticholinergic therapy for their symptoms of frequency and urgency.
Phase:
Phase 4
Details
Lead Sponsor:
State University of New York at Buffalo
Collaborator:
Astellas Pharma Inc
Treatments:
Mirabegron